Eton Pharmaceuticals announced that the United States Patent and Trademark Office has granted the company’s U.S. Patent Application No. 18/113,458, which covers the company’s ET-400 product candidate’s proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 and is expected to be listed in the FDA’s Orange Book upon the product’s approval. The company has additional patent applications related to the product under review with the USPTO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ETON:
- Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
- Eton Pharmaceuticals Launches Nitisinone Capsules for HT-1
- Eton Pharmaceuticals announces availability of Nitisinone Capsules
- Correction: Eton Pharmaceuticals announces availability of Nitisinone Capsules
- Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules